Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates

14 Nov 2025 14:51 CET

14 November 2025: Reference is made to the stock exchange announcements
published by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025,
and subsequent announcements, regarding the contemplated fully underwritten
rights issue in the Company raising gross proceeds of NOK 130 million (the
"Rights Issue").

In connection with the Rights Issue, tradable subscription rights have been
allocated to, inter alia, certain of the Company's primary insiders and their
close associates.

Please see the attached notifications of trade for further information regarding
the primary insiders' and their close associates' receipt of tradable
subscription rights in the Rights Issue.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email:(soug@oncoinvent.com)

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and Section 5-12 of the Norwegian
Securities Trading Act.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases in the peritoneum post-surgery, harnessing the benefits of
modern radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial in ovarian cancer is
currently ongoing in the US and Europe. Early clinical efficacy data are highly
encouraging, and no serious toxicity or safety concerns have been reported to
date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug
products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo
Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly
target microscopic metastases in the abdominal cavity following surgery.
Radspherin® is currently in development as a post-surgical treatment for
patients with cancer that has spread to the abdominal cavity - a group with very
limited treatment options today. The drug candidate offers a distinctly unique
therapeutic approach with several differentiating features, including the use of
radium-224, single-dose treatment with a sustained therapeutic effect, non
-systemic administration, direct targeting and an exceptional dose-to-tumor
ratio, maximizing efficacy while limiting harm to healthy tissue

More information:
Access the news on Oslo Bors NewsWeb site

659775_2025_11_14_PDMR_Attachment2.pdf